Wedbush Maintains Neutral on Compass Therapeutics, Lowers Price Target to $0.9
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wedbush analyst Robert Driscoll maintains Compass Therapeutics (NASDAQ:CMPX) with a Neutral and lowers the price target from $1 to $0.9.
Wedbush analyst Robert Driscoll maintains Compass Therapeutics (NASDAQ:CMPX) with a Neutral and lowers the price target from $1 to $0.9.
